Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xinyu, Zhang, Shouyue, Deng, Yun, Wang, Peiqi, Hou, Qianqian, Xu, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159743/
https://www.ncbi.nlm.nih.gov/pubmed/30294272
http://dx.doi.org/10.3389/fphar.2018.01050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159743/
https://www.ncbi.nlm.nih.gov/pubmed/30294272
http://dx.doi.org/10.3389/fphar.2018.01050

Ejemplares similares